NewGenIvf Group Limited is a comprehensive fertility services provider in Asia helping couples and individuals obtain access to fertility treatments. The Company offers services, such as Mitochondrial Replacement Therapy In Reproductive, Intrauterine Insemination (IUI), Mitochondrial replacement therapy (MRT) techniques, In Vitro Fertilization (IVF) and Intracytoplasmic Sperm Injection (ICSI), semen analysis, testicular / epididymal sperm aspiration or extraction / percutaneous epididymal sperm aspiration, embryo transfer, chromosome screening and egg freezing. The Company’s clinics are located in Thailand, Cambodia, and Kyrgyzstan, and present a full suite of services for its patients, including comprehensive infertility and assisted reproductive technology treatments, egg and sperm donation, and surrogacy, in the appropriate jurisdictions. MRT involves an additional egg from a third person, and manipulating both the recipient egg and the donor egg.
BörsenkürzelNIVF
Name des UnternehmensNewGenIvf Group Ltd
IPO-datumFeb 15, 2022
CEOMr. Claudius Tsang
Anzahl der mitarbeiter76
WertpapierartOrdinary Share
GeschäftsjahresendeFeb 15
AddresseLevel 39, Marina Bay Financial Centre
Stadt
BörseNASDAQ Capital Market Consolidated
LandSingapore
Postleitzahl018983
Telefon6568185796
Websitehttps://newgenivf.com/
BörsenkürzelNIVF
IPO-datumFeb 15, 2022
CEOMr. Claudius Tsang
In den vergangenen 5 Jahren wurden insgesamt
0.00
USD an Dividenden ausgeschüttet.

Keine Daten